Wire flash
Dongxing Medical plans to set up a controlled subsidiary with 20 mln yuan to enter brain-computer interface sector
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Dongxing Medical (301290.SZ) announced on September 22 that it plans to establish a controlling subsidiary, Changzhou Lingnao Intelligent Technology Co., Ltd. (name pending), in partnership with its controlling shareholder and actual controller, Wan Shiping, through his directly controlled entity Guoxing Investment. The move is a strategic response to China's escalating national policies supporting the brain-computer interface (BCI) industry, including a 2025 directive from seven ministries to build a globally competitive BCI ecosystem by 2030 and the inclusion of BCI as one of six future industries in the 15th Five-Year Plan (2026). The subsidiary will have a registered capital of RMB 30 million, with Dongxing contributing RMB 20 million (66.67%) and Guoxing Investment contributing RMB 10 million (33.33%). Upon completion, Lingnao Intelligent will be consolidated into Dongxing Medical's financial statements as a controlled subsidiary, aiming to extend the company's industrial chain and cultivate new profit growth points.
Source report
Hong Kong, September 22 — Dongxing Medical (301290.SZ) announced plans to jointly establish a new subsidiary focused on brain-computer interface (BCI) technology, in response to recent national policy support for the emerging industry.
Strategic Background
The company noted that China has been intensifying its push into the BCI sector in recent years:
- In August 2025, seven government departments including the Ministry of Industry and Information Technology issued implementation guidelines, aiming to build an internationally competitive BCI industry ecosystem by 2030.
- In March 2026, the "15th Five-Year Plan" officially designated BCI as one of six future industries.
Investment Details
In line with its strategy to respond to national BCI industry policies, extend the industrial chain, and cultivate new profit growth points, Dongxing Medical will invest alongside Guoxing Investment — a company directly controlled by its controlling shareholder and actual controller, Mr. Wan Shiping.
The new entity, tentatively named Changzhou Lingnao Intelligent Technology Co., Ltd. (subject to final approval by market supervision authorities), will have a registered capital of RMB 30 million.
| Investor | Contribution (RMB) | Ownership Stake | |---|---|---| | Dongxing Medical | 20 million | 66.67% | | Guoxing Investment | 10 million | 33.33% |
Impact
Upon completion of the investment, Lingnao Intelligent will be consolidated into Dongxing Medical's financial statements as a controlled subsidiary. The company stated that the investment will not affect its daily operations or development, and that risk control measures will be implemented.
Source
格隆汇Eastern
Part of this Story
Dongxing Medical Plans Subsidiary Lingnao Intelligent to Enter Brain-Computer Interface Industry